Sign In
NewsRadar

AIMM Therapeutics

AIMM is a biotech company developing therapeutic human monoclonal antibodies and is located at the Academic Medical Center (AMC) of the University of Amsterdam. It capitalizes on a technology to immortalize human B cells enabling isolation of cloned cell lines that produce antibodies of high clinical value. This technology has been developed by Professor Spits while working at the Netherlands Cancer Institute (NKI) and subsequently at the AMC.

• Show past press releases
• Edit this company

Contact Information
Address:
 
 
Phone:
Fax:
Web:
Contact:
 
 
Meibergdreef 45
Amsterdam 1105 BA
Netherlands
+31 (0)20 566 50 56
+31 (0)20 566 91 68
http://www.aimmtherapeutics.com
Willem J. van Oort
+31 (0)20 566 50 56

Company Facts
Founded:Dec 2004
Founders:
CEO:Willem J. van Oort
CTO or technical lead:Hergen Spits
CFO or finance director:
Head of Sales:
Head of Marketing:

Stage:Early Stage
Category:Biotechnology & Healthcare
Sector:Biotechnology
Employees:
Profitability:
Funding raised:Yes
Funding sought:
Seeking Partnerships:

Non-executive Board Members

Key Customers

Key Business Partners

Key Competitors

Capital Raised
DateSizeInvestors
To view this information you must be signed in and subscribed to the online dataservice, sign in here.

To read more about the Online data service click here

Public Offerings
DateTypeExchange
No public offerings


Data


26,008
Tech investments
From our Online Data Service
16,823
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Aug 19€7.0MAgriculture related
Aug 19€9.0MInternet commerce
Aug 19€10.0ME-Commerce
Aug 19€63.0MBusiness applications
Aug 16€16.0ME-Commerce
Aug 16€6.0MBusiness applications
Aug 15€20.0MGames

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises 1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.